ORIGINAL ARTICLE

Predictors of talc slurry pleurodesis success in patients with malignant pleural effusions

CrossMark

P.S. Santos [a,*], M.A. Marques [a], C. Cruz [a], H. Monteiro [b], F. Fradinho [a]

[a] Pulmonology Unit, Centro Hospitalar e Universitário de Coimbra - Hospitais da Universidade de Coimbra, Coimbra, Portugal
[b] Public Health Unit, ACeS Porto Ocidental, Porto, Portugal

Abstract

Introduction: Malignant pleural effusions are an important burden of malignant disease. Slurry talc pleurodesis remains one of the most common and effective therapeutic options.

Aim: Investigate the predictive factors related with the efficacy of this technique in malignant pleural effusions.

Methods: Retrospective analysis of all pleurodesis performed during a 10-year period in a Pulmonology Unit. All demographic and clinical data were collected, including the histologic tumoral type and the biochemical, microbiological and cytological fluid features. Efficacy was defined as the lack of recurrence of pleural effusion. It was used Kaplan–Meyer analysis to estimate overall survival.

Results: From a total of 202 patients submitted to pleurodesis (47% men; mean age 66.9 ± 12.02 years). Light's criteria identified 86.6% as exudates. We found 85.1% survival at 30-day post-pleurodesis, which means the therapy used has significant success. A logistic regression model applied explained that variance in post-pleurodesis events was mostly due to age and gender rather than pleural biochemical factors ($X^2_{(5)} = 44.648$, $p < 0.001$, R^2 28.3%).

Conclusion: This study suggests that clinical evaluation of biochemical values, bacteriological results and malignant tumor diagnosis may not be enough to predict post-pleurodesis relapse with high accuracy. Furthermore, we observed, in ten years of pleurodesis performed in our Hospital, that pleurodesis is an effective life prolonging therapy for patients that fit the criteria for this intervention.

Introduction

Malignant pleural effusions (MPE) are an important burden of malignant disease, leading to a significant reduction of quality of life with progressive dyspnea, dry cough, chest pain

* Corresponding author.
  E-mail address: pedrorssantos@gmail.com (P.S. Santos) .

and reduced physical activity.[1-4] Lung and breast neoplasms are responsible for 75% of all MPE and the mean survival time is 3–13 months.[5-9]

Despite management of underlying malignancy with chemo/radiotherapy, MPE may persist or recur and requires palliative interventions in order to control or alleviate the symptoms.[2,6,10]

Several palliative treatment options are available including thoracentesis or talc pleurodesis.[2,6,10] Thoracentesis is easy to perform, but has a 98% recurrence rate at 30 days.[6,11] Pleurodesis prevent re-accumulation of the effusion and thereby of symptoms, and avoid the high cost and physical and emotional trauma caused by repeated hospitalization of thoracocentesis.[1,12] Several techniques and various agents have been used for this purpose, with different efficacy. Commonly used sclerosants are talc, tetracycline derivatives and bleomycin. Talc pleurodesis gives a success rate of 81 to 100%, which is in contrast to 65 to 76% achieved with tetracycline and its derivatives and 61% for bleomycin.[13,14] Talc pleurodesis can be made by talc slurry via tube thoracostomy or talc insufflation via thoracoscopy.[15-20]

Unfortunately, pleurodesis fails in 10–40% of patients, with associated marked cost and morbidity. So, the identification of various clinical and biochemical parameters in predicting pleurodesis outcomes, may help to identify which patients would benefit the most from pleurodesis.[21,22]

The purpose of this study is to investigate the predictive factors related to the efficacy of slurry talc pleurodesis in malignant pleural effusions.

Methods

The researchers did a retrospective analysis of all talc pleurodesis performed during a 10-year period in a Pulmonology Unit at Centro Hospitalar e Universitário de Coimbra.

Talc slurry administration via chest tube

In all cases, pleurodesis was performed by talc slurry via a chest tube. A dose of 5 grams of sterile, asbestos-free talc (Steritalc® F2, manufactured by Novatech, France) mixed with 90 ml of sterile saline and 10 ml of lidocaine 1% was instilled through the chest drain, which was clamped for 6 h after the procedure. Chest drain was removed when the chest radiograph confirmed satisfactory lung expansion and the total 24-hour drainage was less than 150 ml, with no air leak. Another chest radiograph was done for all patients a few hours post chest drain removal and if satisfactory, patients were discharged.

Data collection

All demographic and clinical data available were collected, including the histologic tumor type and the biochemical (pH, LDH, albumin, proteins, glucose), microbiological and cytological fluid features. Efficacy was defined as the lack of recurrence of pleural effusion (relapse) during the period of analysis.

Statistical analysis

We used a Kaplan–Meyer analysis to estimate average survival. To identify factors affecting efficacy and survival we used univariate and multivariate analysis. Data were statistically described in terms of mean ± standard deviation (±SD), or frequencies (number of cases) and percentages when appropriate. Comparison of numerical variables between the study groups was done using Mann Whitney U test for independent samples when data were not normally distributed. For comparing categorical data, Chi square (χ^2) test was performed ($p < 0.05$). All statistical calculations were done using computer program SPSS version 21 (95% Confidence Interval always assumed).

Results

A total of 202 patients were submitted to talc pleurodesis (47% men; mean age 66.9 ± 12.02 years). Light's criteria identified 86.6% as exudates and all patients had a positive cytology and histology for malignant disease (64.4% lung cancer; 15.3% breast cancer; 8.4% hematological cancer; 7.4% gynecological cancer; 2.5% intestinal cancer; 2% skin cancer). There was a distinct distribution of cases, where Lung Tumor was the most frequent among relapse and non-relapse post pleurodesis intervention, when compared to other histological tumor types. With the exception of skin tumor (with only 4 cases), we observed that post-pleurodesis non-relapse was more frequent among all groups ($X^2_{(5)} = 13,773$; $p = 0.017$). Pleurodesis was effective in 70.3% of all cases.

Bivariate analysis

Two types of analysis were performed: one considering cut-off values and their association with post pleurodesis results; and the other comparing mean values between post pleurodesis results.

There was a higher frequency of male patients with relapse than female patients (54.2%, $n = 59$), but there was no statistically significant difference between groups, when comparing relapse events in relation to gender ($X^2_{(1)} = 1.506$; $p = 0.278$). Male patients were also 31.6% more likely to suffer from post-pleurodesis pleural effusion relapse (OR = 0.684 [0.372;1.257]).

We evaluated correlation between different relevant variables for both post-pleurodesis events in order to identify influence factors on survival. Statistically, significant observations were found for the relapse group survival in relation to cell count ($r = 0.301$, $p = 0.021$). The non-relapse group survival had a weak correlation with proteins and LDH levels found at the pleural effusion (respectively, $r = 0.289$ and $r = -0.177$), $p < 0.05$.

Considering cut-off values

We applied Chi-square tests considering the cutoff values for biochemical results of the pleural fluid (pH, glucose, proteins, LDH, cell count). We observed a statistically significant association between post-pleurodesis relapse and all other variables, except LDH (Table 1).

Table 1 Bivariate Analysis of categorical variables, comparing with post-pleurodesis relapse event.

	Relapse			
	Yes ($n = 59$)	No ($n = 143$)		
pH > 7.20	59	127	$X^2_{(1)} = 7.169^*$	
pH < 7.20	0	16	$p = 0.007$	
Glucose > 60	56	117	$X^2_{(1)} = 5.827^*$	OR = 4.148
Glucose < 60	3	26	$p = 0.025$	[1.204;14.289]
Proteins > 3.1	59	118	$X^2_{(1)} = 11.772^*$	
Proteins < 3	0	25	$p = 0.001$	
LDH < 1000	55	122	$X^2_{(1)} = 2.407$	OR = 2.367
LDH > 1000	4	21	$p = 0.090$	[0.776;7.222]
Cell count > 1000	41	68	$X^2_{(1)} = 8.092^*$	OR = 2.512
Cell Count < 1000	18	75	$p = 0.005$	[1.319;4.784]

* $p < 0.05$, result statistically significant.

Figure 1 Kaplan–Meier Survival Curve, log rank test $p = 0.01$, alpha < 0.05.

Considering mean values

We applied non-parametric tests (due to K-S, $p < 0.05$) to test the association between relapse and age and the biochemical results of pleural fluid (pH, glucose, proteins, albumin LDH, cell count). We observed a statistically significant association between post-pleurodesis relapse event and median cell count value (Table 2).

Survival analysis

There was a significant difference in survival times between the groups (log rank test $p = 0.01$, alpha < 0.05). The Kaplan–Meier survival curve presents an average survival estimate for the non-relapse group of 400 days [295; 506 (IC95%)] and for the relapse group estimate was 170 days [127; 273 (CI95%)], with a 85.1% success rate at 30 days ($n = 47$) (Fig. 1).

Explanatory factors analysis

A logistic regression was performed to ascertain the effects of biochemical indicators in the pleural fluid (according to cut-off values), age, gender, type of diagnosis and fluid characteristics by cell count (transudate versus exsudate) on the likelihood that patients have post pleurodesis relapse (Table 3).

The logistic regression model was statistically significant ($X^2_{(5)} = 44,648$, $p < 0.001$). The model applied explained 28.3% (Nagelberke R^2) of the variance in post-pleurodesis events and correctly classified 73.3% of cases. Males were 2.48 more likely to suffer relapse than females. Increasing age was associated with an increased likelihood of having a relapse event, but glucose below 60 mg was associated with a reduction in the likelihood of exhibiting relapse events. [AUROC value = 0.75 (95%C.I. 0.685 to 0.818)].

Discussion

In a general hospital, twenty-five percent of all pleural effusions are secondary to cancer. Patients with cancers frequently develop recurrent MPEs secondary to their disease.[20] Normally, more than 90% of MPEs are exudates.[7] However, we found in our study 13.4% of transudates, which can be explained by the increase of hydrostatic pressure as a result of congestive heart failure, decrease in oncotic pressure from hypoalbuminia or increase in the normal negative pressure (more negative intrathoracic pressure) secondary to atelectasis.[20]

Talc pleurodesis is an effective treatment for the control of malignant pleural effusions (MPEs) to maintain the patient's quality of life, as many already suffer from poor general condition.[5,13,15,20,23] Recent data have established that talc pleurodesis will fail in about 30% of patients,[3] which is consistent with our results of 29.7% relapse post-pleurodesis.

In this study, we investigated the predictive factors related with the efficacy of slurry talc pleurodesis in MPEs.

Age and gender had no statistical significance between groups ($p > 0.05$), but there was a tendency for males to have

Table 2 Bivariate Analysis of continuous variables, comparing with post-pleurodesis relapse event.

	Relapse		Man U	p value
	Yes ($n = 59$)	No ($n = 143$)		
Age			$U = 3669.500$	0.146
Median	66	69	$Z = 0.146$	
pH			$U = 3617.500$	0.111
Median	7.56	7.52	$Z = -1.592$	
Glucose			$U = 3876.500$	0.365
Median	93	98	$Z = -906$	
Proteins			$U = 3886.500$	0.379
Median	4.2	4.5	$Z = -0.880$	
Albumin			$U = 4201.500$	0.964
Median	2.5	2.7	$Z = -0.045$	
LDH			$U = 3731.000$	0.197
Median	359.0	286.0	$Z = -1.291$	
Cell count			$U = 3230.000^*$	0.009[*]
Median	1300	1000	$Z = -2.619$	

[*] $p < 0.05$, result statistically significant.

Table 3 Results of binary logistic regression (95%CI), Hosmer Lemeshow ($X^2_{(8)} = 9.389$, $p = 0.311$).

Variables	B-coefficient	Standard Error	Odds ratio	95% CI	Wald (df 1)	p
Gender (categorical)	0.909	0.345	2.481	(1.261;4.881)	6.922	0.009
Age	0.036	0.015	1.037	(1.008;1.067)	6.150	0.013
Glucose pleural effusion (categorical)	−1.412	0.680	0.244	(0.064;0.923)	4.319	0.038

higher risk of suffering from pleural effusion relapse post pleurodesis interventions (31.6%).

Bivariate analysis of biochemical values reveals that some variables at pathological levels do not translate into higher relapse events. Alsayed et al.[22] demonstrated that low pH and glucoses levels together with higher LDH level are related to poorer response to sclerosant agent and shorter mean survival. However, in a meta-analysis of the primary data from multiple cases series it was found that more than 50% of patients with low pleural fluid pH had successful pleurodesis. Therefore, pleural fluid pH had only modest predictive value for predicting symptomatic failure and should be used with caution.[25,26]

Glicosis and pH value had a significant statistical association with post-pleurodesis relapse events ($p < 0.05$), but the pathological values of pH < 7.30 or glucose < 60 mg/dl are more often found in the no-relapse group. This suggests that there might be other confounding factors that influence relapse events which were not taken into account like comorbidities such as diabetes. Pantazopoulos et al.[24] in a retrospective analysis excluded diabetes mellitus and other causes of hyperglycemia and concluded that pleural glucose levels could be a reliable predictor of pleurodesis failure in patients without conditions that could lead to hyperglycemia.

When looking at biochemical values as continuous values and its difference when comparing post-pleurodesis groups, we observe that there is no statistically significant correlation. The exception was pleural fluid differential cell count, where a higher cell count was significantly associated with relapse group when compared to the non-relapse group (Med = 1300 and Med = 1000, respectively, $p = 0.009$).

As expected, survival correlated with biochemical parameters, but not all factors were found to have significant correlation in each group, particularly in the relapse group. This might suggest that the relapse group had more confounding factors that might play an important role as predictors for relapse events which need to be taken into account when doing research on post-pleurodesis events. Indeed, survival had a negative correlation with glucose levels in the pleural effusion ($r = -238$, $p = 0.070$) in the relapse group.

This sample had a median survival time consistent with the literature at 30 day post-pleurodesis survival (85, 1%).[5,15]

Considering that the mean survival time without treatment is 3–13 months,[5–9] the pleurodesis technique applied was also found to have significant success for both groups – with or without relapse. The average survival period for the relapse group was 167 days [CI95%:(124.27;210.51) – P$_{50}$ = 97 days] and for the non-relapse group average survival was 283.43 days [CI95%(215.71;351.14) – P$_{50}$ = 141]. This means that optimal results were found after post-pleurodesis for the sample observed and pleurodesis remains a reasonable palliative option, as it provides a significant increase in survival chances (even with a relapse event) beyond the 3 months of survival without treatment.

A logistic regression model analysis was performed and showed age and gender as post-pleurodesis predictors of relapse events, while glucose cut-off variable was not a

predictor for these events. One of the limitations of this study might be the sample size, in which small deviations can interfere with the model.

Conclusion

This study suggests that clinical evaluation of biochemical values, bacteriological results and malignant tumor diagnosis may not be enough to predict post-pleurodesis relapse with high accuracy. Even though age and gender might influence outcome, the application of the logistic regression model suggests that more factors are involved. In short, we observed in ten years of pleurodesis performed in our Hospital, a significant statistical increase in patient survival.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Conflicts of interest

Authors declare no conflict of interest.

References

1. Ibrahim IM, Dokhan AL, El-Sessy AA, Eltaweel MF. Povidone-iodine pleurodesis versus talc pleurodesis in preventing recurrence of malignant pleural effusion. J Cardiothorac Surg. 2015;10:64.
2. Özkul S, Turna A, Demirkaya A, Aksoy B, Kaynak K. Rapid pleurodesis is an outpatient alternative in patients with malignant pleural effusions: a prospective randomized controlled trial. J Thorac Dis. 2014;6:1731–5.
3. Thomas R, Francis R, Davies HE, Lee YC. Interventional therapies for malignant pleural effusions: the present and the future. Respirology. 2014;19:809–22.
4. Schulze M, Boehle AS, Kurdow R, Dohrmann P, Henne-Bruns D. Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients. Ann Thorac Surg. 2001 Jun;71:1809–12.
5. Marchi E, Vargas FS, Madaloso BA, Carvalho MV, Terra RM, Teixeira LR. Pleurodesis for malignant pleural effusions: a survey of physicians in South and Central America. J Bras Pneumol. 2010;36:759–67.
6. Olden AM, Holloway R. Treatment of malignant pleural effusion: PleuRx® Catheter or talc pleurodesis? A cost-effectiveness analysis. J Palliative Med. 2010;13:59–65.
7. Zarogoulidis K, Zarogoulidis P, Darwiche K, Tsakiridis K, Machairiotis N, Kougioumtzi I, et al. Malignant pleural effusion and algorithm management. J Thoracic Dis. 2013;5 Suppl 4:S413–9.
8. Rodrîguez-Panadero F, Borderas Naranjo F, López Mejîas J. Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series. Eur Respir J. 1989;2:366–9.
9. Martínez-Moragón E, Aparicio J, Sanchis J, Menéndez R, Rogado MC, Sanchis F. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration. 1998;65:108–13.
10. Neragi-Miandoab S. Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer. 2006;54:1–9.
11. Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, et al. Management of malignant pleural effusions. Eur Respir J. 2001;18:402–19.
12. Mohsen T, Zeid A, Meshref M, Tawfeek N, Tawfeek N, Redmond K, Ananiadou OG, et al. Local iodine pleurodesis versus thoracoscopic talc insufflation in recurrent malignant pleural effusion: a prospective randomized control trial. Eur J Cardiothorac Surg. 2011 Aug;40:282–6.
13. Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ, BTS Pleural Disease Guideline Group. BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65 Suppl 2:ii32–40.
14. Lee P. Point: Should thoracoscopic talc pleurodesis be the first choice management for malignant effusion? Yes. Chest. 2012;142:15–7.
15. Inoue T, Ishida A, Nakamura M, Nishine H, Mineshita M, Miyazawa T. Talc pleurodesis for the management of malignant pleural effusions in Japan. Intern Med. 2013;52:1173–6.
16. Bhatnagar R, Laskawiec-Szkonter M, Piotrowska HE, Kahan BC, Hooper CE, Davies HE, et al. Evaluating the efficacy of thoracoscopy and talc poudrage versus pleurodesis using talc slurry (TAPPS trial): protocol of an open-label randomised controlled trial. BMJ Open. 2014;4:e007045.
17. Mummadi S, Kumbam A, Hahn PY. Malignant pleural effusions and the role of talc poudrage and talc slurry: a systematic review and meta-analysis. Version 2. F1000Res. 2014;3:254 [revised 2015 Feb 17].
18. Xia H, Wang XJ, Zhou Q, Shi HZ, Tong ZH. Efficacy and safety of talc pleurodesis for malignant pleural effusion: a meta-analysis. PLoS One. 2014;9:e87060.
19. Dresler CM, Olak J, Herndon JE II, Richards WG, Scalzetti E, Fleishman SB, et al. Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Malignant Pleural Effusion. Chest. 2005;127:909–15.
20. Putnam JB Jr. Malignant pleural effusions. Surg Clin North Am. 2002;82:867–83.
21. Shehata S, Sileem A, El-Fakharany K. Pleural fluid CRP, LDH, and pH as predictors of successful pleurodesis in malignant pleural effusions. Egyptian J Chest Dis Tuberculosis. 2015;64:593–9.
22. Alsayed S, Marzouk S, Abelhalim S, Mousa E. Malignant pleural effusion biomarkers as predictor for chemical pleurodesis success. Egyptian J Chest Dis Tuberculosis. 2015;64:153–60.
23. Gawron G, Gabryś J, Barczyk A. Talc slurry pleurodesis via chest tube in department of pulmonology-a 24-case study. Pneumonol Alergol Pol. 2013;81:439–47.
24. Pantazopoulos I, Xanthos T, Vlachos I, Kakoulas Z, Stroumpoulis K, Chalkias A, et al. Pleural fluid glucose: A predictor of unsuccessful pleurodesis in a preselected cohort of patients with malignant pleural effusion. J BUON. 2014;19:1018–23.
25. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data. Chest. 2000;117:87–95.
26. Huggins JT, Doelken P, Sahn SA. Intrapleural therapy. Respirology. 2011;16:891–9.